NASDAQ · ABSI

Absci Corporation

$7.56 -$0.51 (-6.32%) 1D After hours

Key Metrics

$1.37B
Market cap
P/E · TTM
Revenue · TTM
−$118.44M
Net income
EPS · TTM $-0.95
Dividend yield
Free cash flow −$98.51M
Beta · 1Y 3.16
EBITDA · TTM −$106.95M
Gross margin

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 24
    From its Jul 2 high, the share price fell 35%.

    Peak close $11.62 on Jul 2; trough close $7.56 on Jul 24. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -35%
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Jun 24
    The stock moved +36.0% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Jun 24
  • Jun 4
    The stock moved +23.6% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Jun 4

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$1.37B
Enterprise value
Shares outstanding169.4M
52-wk range$2.24 – $12.06
Avg volume · 20D2.0M
Net cash
Book value / share$1.38
IndustryServices-Commercial Physical & Biological Research
ExchangeNASDAQ
About Absci Corporation
IPO dateJul 22, 2021
Employees140

Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E
P/S
P/FCF
EV/EBITDA
EV/Sales
Graham №

Profitability

Gross
Operating
Net
FCF
ROE / ROIC -67.5% · -256.0%

Financial Health

Current ratio6.59
Quick ratio
Debt / equity
Debt / EBITDA
Net cash
Working capital$111.94M

Cash Flow · TTM

Operating CF −$97.39M
Capex −$1.11M
Free cash flow −$98.51M
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

2 / 9
Weak fundamentals · 2 of 9 signals passing

Altman Z-Score

Insufficient balance-sheet inputs

Graham Number vs Price

Requires positive earnings and book value
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings